Global Panic Attack Treatment Market Size and Trends

Global Panic Attack Treatment Market is expected to reach US$ 6.34 Bn by 2030, from US$ 2.14 Bn in 2023, exhibiting a CAGR of 16.8% during the forecast period. Panic attack treatment involves the use of pharmacological and non-pharmacological therapies to manage and reduce the frequency and severity of panic attacks. Panic attacks are episodes of sudden and intense fear, apprehension, and anxiety accompanied by physical symptoms like shortness of breath, palpitations, chest pain, and others. The treatment aims to control the symptoms and prevent recurrent attacks that can severely impair normal functioning.

The key advantages of timely and effective panic attack treatment include preventing agoraphobia, improving quality of life, reducing hospital visits and healthcare costs, and lowering risk of suicide. The market growth is driven by rising burden of anxiety and panic disorders, strong pipeline of novel drugs, and increasing awareness about mental health.

Global panic attack treatment market is segmented into drug class, route of administration, distribution channel, and region. By drug class, the selective serotonin reuptake inhibitors (SSRIs) segment accounts for the largest share owing to their efficacy, safety, and favorable side effect profile. SSRIs are usually the first line of treatment for panic disorders.

Global Panic Attack Treatment Market- Trends

Increasing adoption of mindfulness meditation and yoga: Growing research highlighting the benefits of mindfulness-based meditation and yoga in reducing anxiety symptoms is boosting its adoption in clinical settings. Meditation techniques help patients by increasing awareness about thoughts, physical sensations and environment while yoga lowers cortisol, heart rate and blood pressure. Companies are increasingly recommending yoga therapy and mindfulness training as adjunct to pharmacotherapy to lower drug dosages. Their non-invasive approach and ability to improve stress resilience make these approaches viable options.
Use of ketamine and psychedelics in treatment-resistant cases: Ketamine, a dissociative anesthetic, is being increasingly explored for its rapid antidepressant effects in those unresponsive to conventional treatment. Studies indicate it can reset neural circuits dysregulated in mood disorders. Similarly, psychedelics like psilocybin and MDMA are also being clinically tested for anxiety disorders, especially in cases resistant to existing interventions. These expanding therapeutic applications are expected to provide new assistance to patients poorly controlled with first-line medications.
Growth in generics and OTC segments: The market has witnessed significant growth of generics drugs, owing to patent expiration of several blockbuster drugs. The greater affordability of generic versions is increasing penetration in price sensitive markets. Companies are also introducing OTC anti-anxiety supplements and herbal formulations to tap into consumer demand for non-prescription alternatives. The expected approval of other key drugs like Lybalvi, Apomine, and biosimilars of Lexapro, Cymbalta, and Effexor XR allow wider access to cost-effective pharmacological interventions.
Direct-to-consumer advertising and digital marketing: Pharmaceutical companies are extensively utilizing direct-to-consumer advertising and targeted promotional campaigns on digital media platforms for greater consumer outreach. Digital ads offer geo-targeting and personalized messaging to specific demographics. Companies are seeking to reduce stigma by portraying mental illnesses as common disorders. Consumer self-diagnosis and empowerment are expected to expand the patient pool. Social media is also being leveraged to spread awareness through influencer marketing. Such initiatives promise lucrative opportunities for player growth.